Background: Asian Blepharoplasty (AB) is one of the most commonly performed aesthetic procedures today. Despite the increasing demand for AB and advancements in surgical techniques, creating an optimal upper eyelid cr...
详细信息
Background: Asian Blepharoplasty (AB) is one of the most commonly performed aesthetic procedures today. Despite the increasing demand for AB and advancements in surgical techniques, creating an optimal upper eyelid crease remains difficult. This study aimed to determine whether removing the preaponeurotic fat pad (PAF) had any effect on the revision surgery rates following primary Asian blepharoplasty. Methods: A retrospective comparative analysis was conducted on patients who underwent primary AB between January 2016 and December 2020. Patients were divided into PAF removed and PAF not removed groups. The outcomes in the groups were compared by the frequency of revision surgery following primary AB using the chi-square test (p Results: The study included 480 patients, 442 (92%) female and 38 (8%) male, and the final outcome was evaluated after 6 months postoperatively. 412 (86%) patients were observed to have PAF pads intraoperatively, while 68 (14%) had minimal/no PAF pads. In total, 115 (24%) patients underwent revision surgery, of whom 31 (27%) had PAF removed, 66 (57%) had PAF not removed, and 18 (16%) had minimal/no PAF noted. When compared to the PAF not removed group, the PAF removed group showed a significantly lower frequency of revision surgery between the two groups of patients (p = 0.0001). Conclusion: In the final outcome, not removing the PAF in primary AB indicated a strong association with an increase in revision surgery. The removal of PAF in primary AB showed a better overall outcome and patient satisfaction.
Introduction:Griseofulvin is an antifungal drug belonging to Biopharmaceutical Classification System(BCS class II)having low ***:To formulate,evaluate and enhance the dissolution of poorly water soluble drug Griseoful...
详细信息
Introduction:Griseofulvin is an antifungal drug belonging to Biopharmaceutical Classification System(BCS class II)having low ***:To formulate,evaluate and enhance the dissolution of poorly water soluble drug Griseofulvin by using solid dispersion ***:Six formulations were prepared by solid dispersion method using Polyethylene Glycol(PEG 6000)125 mg,0 mg,62.5 mg,100 mg,25 mg,150 mg and superdisintegrants Crospovidone 0 mg,125 mg,62.5 mg,100 mg,25 mg,150 mg in all batches ***:Satisfactory results were obtained from evaluation of physical characteristics of Griseofulvin tablets including:carr’s compressibility index(17.5±0.19%to 11.76±0.67%),Hausner ratio(1.21±0.01 to 1.13±0.02)and post compression parameters including:thickness(5.16±0.02 mm to 4.57±0.19 mm),friability(0.024%to 0.322%),hardness(4±0.28 kg/cm^(2)to 5±0.57 kg/cm^(2)),disintegration time(14-870 seconds).Conclusions:F3 was best formulation among all formulated batches with in-vitro drug release 30.05%in 10 minutes,69.21%in 30 minutes and 97.11%in 45 *** indicated that formulation F3 batch with PEG 6000 of 62.5 mg and crospovidone 62.5 mg showed increased dissolution.
暂无评论